HC Wainwright Reaffirms Buy Rating for Vor Biopharma (NYSE:VOR)

Vor Biopharma (NYSE:VOR)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $17.50 target price on the stock.

VOR has been the topic of several other reports. Barclays decreased their price target on shares of Vor Biopharma from $10.00 to $3.00 and set an “overweight” rating on the stock in a report on Wednesday, August 14th. Robert W. Baird cut their price target on shares of Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating for the company in a report on Friday, November 8th. JMP Securities reiterated a “market outperform” rating and set a $12.00 price target on shares of Vor Biopharma in a report on Friday, September 6th. Finally, Wedbush reissued an “outperform” rating and set a $11.00 price target on shares of Vor Biopharma in a research report on Monday. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, Vor Biopharma has a consensus rating of “Buy” and a consensus target price of $11.36.

Vor Biopharma Stock Down 3.8 %

Shares of Vor Biopharma stock traded down $0.04 during midday trading on Tuesday, hitting $1.00. The company’s stock had a trading volume of 776,571 shares, compared to its average volume of 511,437. The firm has a market capitalization of $68.67 million, a P/E ratio of -0.61 and a beta of -0.37. The stock has a 50-day simple moving average of $0.78 and a 200-day simple moving average of $0.93. Vor Biopharma has a 1-year low of $0.63 and a 1-year high of $3.14.

Vor Biopharma (NYSE:VOR) last announced its earnings results on Thursday, November 7th. The company reported ($0.40) earnings per share for the quarter, meeting the consensus estimate of ($0.40). As a group, sell-side analysts predict that Vor Biopharma will post -1.55 earnings per share for the current year.

Institutional Trading of Vor Biopharma

Several hedge funds have recently made changes to their positions in the company. Acadian Asset Management LLC increased its position in Vor Biopharma by 51.4% during the 2nd quarter. Acadian Asset Management LLC now owns 81,305 shares of the company’s stock worth $79,000 after purchasing an additional 27,597 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Vor Biopharma by 4.0% in the first quarter. Vanguard Group Inc. now owns 1,812,899 shares of the company’s stock valued at $4,297,000 after buying an additional 69,436 shares during the last quarter. Hsbc Holdings PLC raised its position in shares of Vor Biopharma by 177.0% in the second quarter. Hsbc Holdings PLC now owns 49,038 shares of the company’s stock valued at $51,000 after buying an additional 31,333 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new stake in Vor Biopharma during the second quarter worth approximately $53,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in Vor Biopharma in the 2nd quarter worth approximately $63,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.